Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Renovorx Inc (RNXT)

Renovorx Inc (RNXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
iAccess Alpha Virtual Best Ideas Summer Investment Conference Begins Today ACCESS Newswire - Tue Jun 23, 7:15AM CDT

RALEIGH, NC / ACCESS Newswire / June 23, 2026 / iAccess Alpha's Virtual Best Ideas Summer Investment Conference begins today, bringing together small and micro-cap public companies and investors for a...

ECOR : 7.57 (-9.34%)
BOSC : 4.43 (-0.45%)
MYO : 1.1800 (-0.84%)
AMROF : 0.2350 (+11.90%)
ROC : 4.54 (+4.37%)
EXYN : 5.76 (-6.95%)
ACCS : 6.70 (+1.21%)
SKYX : 1.0200 (+0.99%)
NNBR : 2.63 (-8.68%)
TII : 2.17 (-7.66%)
TI : 5.63 (+0.36%)
MIND : 4.90 (-1.61%)
iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 23–24, 2026 ACCESS Newswire - Thu Jun 18, 8:00AM CDT

RALEIGH, NC / ACCESS Newswire / June 18, 2026 / iAccess Alpha today announced that it will host its Virtual Best Ideas Summer Investment Conference on June 23-24, 2026, bringing together small and micro-cap...

ECOR : 7.57 (-9.34%)
BOSC : 4.43 (-0.45%)
MYO : 1.1800 (-0.84%)
AMROF : 0.2350 (+11.90%)
ROC : 4.54 (+4.37%)
EXYN : 5.76 (-6.95%)
ACCS : 6.70 (+1.21%)
SKYX : 1.0200 (+0.99%)
NNBR : 2.63 (-8.68%)
TII : 2.17 (-7.66%)
TI.TO : 2.98 (-9.42%)
MIND : 4.90 (-1.61%)
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer GlobeNewswire - Thu Jun 11, 7:30AM CDT

MOUNTAIN VIEW, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 0.9530 (+4.64%)
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd GlobeNewswire - Thu Jun 4, 7:30AM CDT

MOUNTAIN VIEW, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies...

RNXT : 0.9530 (+4.64%)
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer GlobeNewswire - Thu May 28, 7:30AM CDT

MOUNTAIN VIEW, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies and...

RNXT : 0.9530 (+4.64%)
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting GlobeNewswire - Tue May 26, 7:30AM CDT

Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic Exposure...

RNXT : 0.9530 (+4.64%)
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th GlobeNewswire - Tue May 19, 7:30AM CDT

MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies...

RNXT : 0.9530 (+4.64%)
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter GlobeNewswire - Thu May 14, 3:05PM CDT

Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™...

RNXT : 0.9530 (+4.64%)
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET GlobeNewswire - Wed Apr 29, 7:30AM CDT

MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies...

RNXT : 0.9530 (+4.64%)
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting GlobeNewswire - Thu Apr 23, 7:30AM CDT

MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 0.9530 (+4.64%)

Barchart Exclusives

If You Crave Dividends, This Tasty Dividend Stock Is a Buy at New 52-Week Lows Barchart - Wed Jun 24, 6:30PM CDT
Domino's Pizza stock fell to a 52-week low on June 23. With a dividend yield of 2.7% and a reasonable valuation, DPZ stock is a decent buy for income-seeking investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.